Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COX-2 Retrospective Study Prompts Review By FDA, Kaiser On Merck’s Vioxx

Executive Summary

A retrospective study conducted on COX-2s and NSAIDs has prompted reviews by FDA and Kaiser Permanente on the use of Merck's Vioxx (rofecoxib)

You may also be interested in...



FDA Postmarketing Surveillance System Adds Kaiser Retrospective Database

FDA will have access to four population-based databases for safety surveillance through its cooperative agreement program beginning in FY 2006, including the newly added Kaiser Permanente California registry

FDA Postmarketing Surveillance System Adds Kaiser Retrospective Database

FDA will have access to four population-based databases for safety surveillance through its cooperative agreement program beginning in FY 2006, including the newly added Kaiser Permanente California registry

Risk Management Guidance Suggests Advisory Cmte Review For RiskMAPs

FDA recommends that advisory committees weigh in on whether a risk minimization action plan is appropriate for a particular drug

Related Content

Topics

UsernamePublicRestriction

Register

PS044568

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel